Biotech Bubble of 1991

The biotech bubble of 1991 was the market’s first major infatuation with genomics and drug discovery as an investment theme, driving a wave of initial public offerings and soaring valuations for companies with no profits and minimal revenue. The bubble deflated sharply in 1992, teaching an enduring lesson about how transformative technologies can seduce investors into abandoning valuation discipline.

The promise of genomics

The biotechnology industry was not new in 1991, but the investment appetite for it was historically unprecedented. The impetus was scientific: the Human Genome Project had begun in earnest in 1990, capturing headlines with its promise to map human DNA and unlock the genetic basis of disease. If the genome could be decoded, the logic went, drug discovery would accelerate exponentially. Diseases would be understood at the molecular level. Pharmaceutical development would move from trial-and-error chemistry to rational design.

This narrative was not merely plausible; it contained genuine seeds of truth. The science was real. DNA sequencing technology was advancing. Gene therapy held theoretical promise. But the investment community, starved for thematic growth stories in the early 1990s, seized on genomics as the secular trend that would drive returns for a generation.

A wave of venture-backed biotech startups prepared for public offerings. Unlike earlier biotech companies, which typically had some clinical candidates or licensing deals, these newer entrants were pure-play genomics: DNA sequencing tools, gene mapping services, or theoretical drug targets identified through genetic analysis. They had no approved drugs, no revenue, and in many cases no clear commercial application. Yet investors bid their shares aggressively.

The IPO frenzy

In 1991, dozens of biotech companies went public at valuations that reflected pure speculation on the transformative power of genetic science. The most famous case was Genentech, an earlier-stage biotech, which had been private but was now a model—a company founded by scientists on a truly innovative platform. The market read this as proof that biotech companies could be built at scale.

The newly public firms attracted retail and institutional capital drawn by the promise of “the next Genentech.” IPO pops were common; a stock offered at $10 might open at $18 on the first day, enriching underwriters and early venture investors but creating a treacherous entry point for later buyers. A fever dream of press coverage accompanied each offering: headlines about “genetic code cracking” and “disease cures on the horizon.”

Investment advisors pitched biotech as a must-own exposure. Professional investors, cognisant that early-stage venture capital had generated remarkable returns in earlier decades, decided they needed biotech exposure in their public portfolios. Mutual funds launched “biotech and genomics” offerings. The sector’s collective market capitalization swelled despite virtually no earnings across the cohort.

Valuation divorced from reality

The disconnect between price and fundamentals became glaringly apparent to anyone paying attention. A typical biotech IPO in 1991 might be valued at $500 million to $1 billion based on ten years of estimated future cash flows—but with assumptions so optimistic they bordered on fantasy. The models assumed that DNA sequence databases alone would spawn profitable therapeutic franchises. They forecast revenue timelines that compressed what typically took 10–15 years of clinical development into 3–5 years.

Few investor conversations centred on the actual scientific and regulatory hurdles. Getting a drug approved required not just identifying a genetic target but conducting phase I, II, and III clinical trials—a process that almost universally took longer and cost more than initial projections. The Food and Drug Administration would not rubber-stamp therapies merely because scientists had found the right gene. Years of human testing lay between genomic discovery and a marketable drug.

Yet this friction was absent from the collective mind during the 1991 mania. The investment thesis was narrative-driven: genomics was revolutionary; these companies owned genomics; therefore they would grow explosively. The due diligence—reading regulatory timelines, understanding the clinical trial process, assessing management execution—was secondary to theme-chasing.

The 1992 correction

By late 1991 and into 1992, the consensus began to crack. Some institutional investors started expressing scepticism. Biotech IPOs that had popped 50–100% on their first day began trading flat or declining. Analysts began asking uncomfortable questions: where were the revenues? What was the path to profitability? How many of these targets would actually yield FDA-approved drugs?

The market’s mood darkened. A combination of factors hastened the decline: rising interest-rate, a rotation out of growth stocks, and the dawning realisation that the initial public valuations were unsustainable. By late 1992, the biotech index had fallen 40–50% from its peak. Many of the 1991 IPOs were trading below their offering price.

The correction was swift and severe enough to deter new biotech offerings for years. Companies that had planned IPOs shelved them. Venture capitalists became more conservative about biotech funding. The narrative of inevitable genomic revolution, so compelling twelve months earlier, suddenly seemed like hubris.

Why the bubble matters

The 1991 biotech bubble was instructive for several reasons. First, it demonstrated that even genuine scientific breakthroughs—and the Human Genome Project was indeed a breakthrough—can catalyse wildly excessive valuations if investors collapse the time horizon. The science was real; the commercial timelines were fantasy. Second, it revealed how difficult it is for markets to distinguish between a transformative technology and an investable asset at a given price. Genomics would ultimately transform medicine, but the companies whose shares traded in 1991 would mostly not be the winners; many were later acquired or went bankrupt, and their 1991 shareholders rarely recouped their investments.

Third, the bubble illustrated the power of narrative over fundamentals in driving capital allocation. Investors with no background in molecular biology or drug development were confident enough to bid billion-dollar valuations on companies with no revenue. The promise was seductive; the discipline was absent.

The 1991 correctionended the first genomics mania but not the underlying logic. Decades later, when CRISPR gene-editing technology emerged, when single-cell sequencing promised to revolutionise oncology, when mRNA platforms proved viable in COVID vaccines, the investment community would again grow euphoric about biotech. But the 1991 lesson persisted in institutional memory: exciting science is not the same as good equity.

See also